China Contract Research Organization (CRO) Industry Report, 2012-2013
  • Feb/2013
  • Hard Copy
  • USD $1,850
  • Pages:65
  • Single User License
    (PDF Unprintable)       
  • USD $1,750
  • Code: ZYM040
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,700
  • Hard Copy + Single User License
  • USD $2,050
      
Compared to Europe and America, China developed pharmaceutical CRO industry 40 years later, with domestic industrial players amounting to over 500, most of which are SMEs. In general, Chinese CRO market scale occupies only 7%-10% of the world’s total, and in 2011-2012 the CRO market size of China approximated RMB22-28 billion.

Considering huge potentials of Chinese phramceutical market, intensive talent resource, relatively low cost and rich spectrum of diseases, foreign enterprises are accelerating to expand CRO market there. Presently, world-renowned CRO companies including Quintiles, Covance, PPD, CRL and ICON have set foot in China by building new establishments and M&As. In China, homegrown leaders cover WuXi AppTec Co., Ltd., Shanghai-headquartered ShangPharma Corporation, and Hangzhou Tigermed Consulting, with the respective revenue in Jan.-Sep., 2012 hitting USD374 million, USD94.47 million and USD29.84 million, the combined proportion of 14% in China CRO market.

In an aim to realize resource sharing and improve overall competitiveness, some domestic pharmaceutical CRO enterprises seek joint development by setting up alliance. A case in point is ABO, which was established in 2005 merging nine research institutes including Academy of Military Medical Sciences, National Institutes for Food and Drug Control, and National Center of Biomedical Analysis, gathering three national engineering centers and seven national engineering technology centers, with sharable hi-tech resources valuing RMB1 billion. In 2012, ABO had 38 corporate members (including Sino Biological Inc. and Pharmaron), with the total area newly increasing by 40,000 sq meters to 270,000 sq meters or more and the total revenue growing by 28.6% year-on-year to over RMB1.8 billion which accounted for 6.4% in Beijing biomedical R&D service industry. And the revenue generated by international orders rose by 14.7% YoY to RMB780 million.

In Jan. 2013, JOINN Laboratories (Beijing), a member of ABO, took over the San Francisco-based R&D and production bases of Bayer, opening a new chapter for Chinese biomedical enterprises’ acquisition of worldwide R&D bases transnational businesses in overseas countries. And JOINN Laboratories is scheduled to lavish USD100 million to set up a 300-mu(1mu=666.7sq meters)US-based Join Innovation Park, in an attempt to provide business incubator, technical support, international cooperation and other services for small-and medium-sized biomedical innovative enterprises in Silicon Valley and China.

The report highlights the followings:
20120114.gif international market, domestic macro- environment and polices, laws and regulations of China CRO industry;
20120114.gif status quo, market scale, competition pattern and development prediction of China CRO industry;
20120114.gif?Operation, CRO business and development dynamics in China of six foreign and five domestic industrial players.

1. Overview of CRO Industry
1.1 Definition & Classification
1.2 Industry Background

2. Development Environment of CRO Industry in China
2.1 International Environment
2.2 Industry Environment
2.3 Policy Environment

3. Market Analysis of CRO Industry in China
3.1 Status Quo
3.2 Market Size
3.3 Competition Pattern
3.4 Regional Market
3.4.1 Beijing
3.4.2Shanghai
3.4.3 Chengdu
3.5 Prospects

4.Key CRO Enterprises Worldwide
4.1 Covance Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Business in China
4.2 PAREXEL International
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Business in China
4.3 PPD
4.3.1 Profile
4.3.2 Operation
4.3.3 Business in China
4.4 Quintiles Transnational Corp.
4.4.1 Profile
4.4.2 Business in China
4.5 Charles River Laboratories International, Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Business in China
4.6 Asymchem Inc.
4.6.1 Profile
4.6.2 Business in China

5.Key CRO Enterprises in China
5.1 WuXi AppTec Co., Ltd.
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Development Trend and Prospects
5.2 ShangPharma Corporation
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development Trend and Prospects
5.3 Venturepharm Laboratories Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Development Trend and Prospects
5.4 Tigermed Consulting Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 Development Trend and Prospects
5.5 Sundia MediTech Co., Ltd.
Classification of CRO
Global CRO Market Size and Growth Rate, 2007-2012
Global Key CRO Organizations and Their Business
Total Industrial Sales and Growth Rate of China’s Pharmaceutical Manufacturing, 2008-2012
Total Industrial Sales of China’s Bio-chemical Pharmaceutical Manufacturing, 2008-2012
Chinese CRO Market Size and Growth Rate, 2007-2012
Classification of Chinese CRO Companies (by Business)
Key M&A Cases of CRO Industry in China, 2007-2011
Regional Distribution of Leading Foreign CROs in China
Revenue and YoY Growth Rate of ABO, 2010-2012
Sponsors of CRO in Zhonguancun (Listed in No Particular Order)
Platform Edge of Shanghai Pharma Engine
Major CRO Enterprises of Shanghai Pharma Engine
Revenue and Operating Profit of Covance, 2009-2012
Revenue of Covance by Business, 2010-2012
Revenue and Operating Profit of PAREXEL, 2009-2012
Revenue of PAREXEL by Business, 2009-2012
Revenue of PAREXEL by Region Worldwide, 2009-2012
Revenue of PPD, 2007-2010
Corporate Advantages of Excel PharmaStudies, Inc.
Revenue and Operating Profit of CRL, 2009-2012
Revenue Breakdown of CRL by Business, 2009-2012
Asymchem Inc’s Companies and Main Businesses in China
Operation of Asymchem Inc.(Tianjin), 2008 & Jan.2009-May, 2009
Branch Distribution of WuXi AppTec Co., Ltd
Revenue and Gross Margin of WuXi AppTec Co., Ltd, 2008-2012
Main Businesses of WuXi AppTec Co., Ltd
Revenue of WuXi AppTec Co., Ltd by Business, 2010-2012
Big Events of WuXi AppTec Co., Ltd, 2011-2012
Revenue and Gross Margin of WuXi AppTec Co., Ltd, 2011-2015E
Distribution of Subsidiaries of ShangPharma Corporation
Four R&D Bases of ShangPharma Corporation
Revenue and Gross Profit of ShangPharma Corporation, 2008-2012
Revenue Breakdown of ShangPharma Corporation by Business, 2009-2011
Shareholding (Joint-stock) Companies of Venturepharm Laboratories Ltd
Revenue and Gross Profit of Venturepharm Laboratories Ltd, 2007-2011
Revenue of Venturepharm Laboratories Ltd by Business, 2010-2011
Number of Cases of Venturepharm laboratories Approved by SFDA, 2002-2011
Seven Subsidiaries and Business Distribution of Tigermed Consulting Co., Ltd
Domestic and Foregin Customer Distribution of Tigermed by Region
Revenue and Profit of Tigermed, 2009-2012
New Contract Value and Average Contract Value of New Contracts of Tigermed, 2009-2011
New Contract Number and Value of Tigermed by Business, 2009-2011
Operating Revenue and Operating Cost of Tigermed by Business, 2009-2011
Revenue Breakdown of Tigermed by Region, 2009-2011
Revenue and Proportion from Clinical Test Technical Service Business of Tigermed, 2009-2011 
Consolidated Gross Margin of Tigermed, 2009-2011
Gross Margin of Tigermed by Business, 2009-2011
Name List and Revenue Contribution of Tigermed’s Top 5 Clients, 2009-2011
Name list and Procurement of Tigermed’s Top 5 Suppliers,2009-2011
Number of Clinical Research Projects of Tigermed by Business  
Clinical Research Projects of Tigermed by Disease 
IPO Investment Projects of Tigermed 
Business Layout of Tigermed after Production of Fundraising Projects

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号